Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640171 · ClinicalTrials.gov registry record · NA
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
A NA study, sponsored by Retina Vitreous Associates of Florida.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT01640171 is a NA study that has completed, run by Retina Vitreous Associates of Florida. The registered enrollment target is 57 participants.
The verdict
NCT01640171, a NA study, has completed, sponsored by Retina Vitreous Associates of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates. A 2010 study showed that in Canada and the incidence of injections grew 8 fold from 2005 to 2007 to 25.9 injections per 100,000 citizens. (Campbell 2010) In 2009, in the United States, over 1 million intravitreal injections were administered to Medicare beneficiaries. (Wykoff 2011) In the year 2011, the four doctors in my retina group administered a total of 6,494 intravitreal injections; in 2010, we administered 5021 intravitreal injections. Even though intravitreal injections are commonly administered, the optimal method of anesthetizing the eye prior to injection has yet to be determined. Some physicians use an anesthetic drop, some a soaked cotton pledget, some use an anesthetic gel and some use subconjunctival injected anesthetic. In 2009, the last time the Procedures and Trends Survey (PAT) (Mittra 2009) conducted by the American Society of Retina Specialists (the largest retina society in the world) asked about anesthetic methods for administering intravitreal injections, the following response was given by the 433 respondents: * Topical anesthetic drop: 21.48% * Topical viscous anesthetic: 23.33% * Topical anesthetic \& soaked cotton-tip or pledget: 29.79% * Subconjunctival injection of anesthetic: 24.02% * Other: 1.39% An editorial in 2011 in the journal Retina, discusses the lack of good studies assessing optimal anesthetic prior to intravitreal injections. (Prenner 2011).
Interventions
- PROCEDURE Xylocaine 2% Injectable Anesthetic
- DRUG Proparacaine Hydrochloride 0.5% Drop
- DRUG Tetravisc 0.5% Gel
- DRUG Acuvail
- DRUG Intra-vitreal Anti-VEGF Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640171
The ClinicalTrials.gov registry entry for NCT01640171 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Retina Vitreous Associates of Florida, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Xylocaine 2% Injectable Anesthetic is the first listed.
NCT01640171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01640171 about?
NCT01640171 is a clinical study titled "Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival". Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates. A 2010 study showed that in Canada and the incidence of injections grew 8...
What is the current status of trial NCT01640171?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2012-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01640171?
The interventions under investigation include: Xylocaine 2% Injectable Anesthetic (PROCEDURE), Proparacaine Hydrochloride 0.5% Drop (DRUG), Tetravisc 0.5% Gel (DRUG), Acuvail (DRUG), Intra-vitreal Anti-VEGF Drug (DRUG).
Who is sponsoring clinical trial NCT01640171?
This trial is sponsored by Retina Vitreous Associates of Florida, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.